Congress targets rising cancer epidemic in young adults with research push
S. 4717 — Asal Sayas National Strategy on Young Adult Cancers Act · Filed by Ed Markey (D-MA) · 1 cosponsor · Introduced Jun 9, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the National Institutes of Health (NIH) to develop a comprehensive national strategy on young adult cancers (ages 18–49) within 18 months, including research priorities, a public education campaign, screening guidance, and a federal clearinghouse. It establishes a Federal Coordinating Committee on Young Adult Cancers with representatives from multiple federal agencies, patient groups, and industry to oversee implementation and report progress to Congress. The bill addresses a documented gap: young adult cancer incidence has risen 79% globally since 1990, yet screening criteria and medical awareness lag behind the disease burden in this age group.
Why we flagged it
The bill's core function is to mandate a federal strategy and coordinating committee for young adult cancer research and awareness—a public health infrastructure measure, not a regulatory change or appropriation. It is straightforward in mechanism and intent.
What the text implies
- The bill does not appropriate funds; implementation depends on future budget decisions and NIH discretionary spending, creating potential for underfunding if Congress does not follow up with appropriations.
- The Federal Coordinating Committee includes 'representatives of the biomedical industry,' which may influence research priorities and screening recommendations toward commercially viable therapies rather than prevention or lifestyle interventions.
- Establishing a National Centers of Excellence program may concentrate resources in academic medical centers, potentially widening access gaps for rural and medically underserved young adults despite the bill's stated equity goals.
- The clearinghouse and education campaign may inadvertently increase screening rates in low-risk populations, raising healthcare costs and anxiety without proportional benefit if screening guidance is not carefully calibrated by cancer type and risk profile.
Who it affects
Ordinary citizens benefit from improved early detection, reduced diagnostic delays (currently 7 months vs. 1 month for older adults), better medical education, and coordinated research into a growing public health threat. The strategy aims to lower barriers to screening and treatment, particularly for underserved populations, with no apparent cost to the public beyond standard federal research funding.
Who stands to gain
- biomedical and pharmaceutical companies
- cancer diagnostic and treatment technology firms
- academic medical centers and research institutions
- clinical trial networks
Named in the bill
National Institutes of Health (NIH), National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), Department of Health and Human Services (HHS), Department of Veterans Affairs (VA), Department of Defense (DoD), Environmental Protection Agency (EPA), National Science Foundation (NSF), Advanced Research Projects Agency-Health (ARPA-H), US Preventive Services Task Force (USPSTF)
Where it stands
1 cosponsor: 1 Democrats.
- Jun 9, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Jun 9, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $1,240,000 in lobbying spend. A filing names 35 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Ed Markey, the sponsor, reported $658,450 in PAC receipts in the 2026 cycle.
- American Cancer Society Cancer Action Network Inc — $1,240,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 9, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Jun 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress targets rising cancer epidemic in young adults with research push” QuorumCivic. https://share.quorumcivic.app/bill/119/s4717 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.